Characterizing the heterogeneity of triple-negative breast cancers using microdissected normal ductal epithelium and RNA-sequencing

Breast Cancer Research and Treatment

Volumn 143, Issue 1, 2014, Pages 57-68

  Radovich, Milan ^a   Clare, Susan E ^a   Atale, Rutuja ^a   Pardo, Ivanesa ^a   Hancock, Bradley A ^a   Solzak, Jeffrey P ^a   Kassem, Nawal ^a   Mathieson, Theresa ^b   Storniolo, Anna Maria V ^a,b   Rufenbarger, Connie ^b   Lillemoe, Heather A ^a   Blosser, Rachel J ^a   Choi, Mi Ran ^a   Sauder, Candice A ^a   Doxey, Diane ^a   Henry, Jill E ^b   Hilligoss, Eric E ^c   Sakarya, Onur ^c   Hyland, Fiona C ^c   Hickenbotham, Matthew ^c   Zhu, Jin ^d   Glasscock, Jarret ^d   Badve, Sunil ^a   Ivan, Mircea ^a   Liu, Yunlong ^a   Sledge, George W ^e   Schneider, Bryan P ^a   more..

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b IU Simon Cancer Center   (United States)

^c Life Technologies   (United States)

^d Cofactor Genomics LLC ^*  (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adjacent normal; Ductal epithelium; Normal breast; RNA seq; TCGA; Triple negative breast cancer

Indexed keywords

CETUXIMAB; DASATINIB; GEFITINIB; IMATINIB; INIPARIB; OLAPARIB; RUCAPARIB; TRANSCRIPTOME;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; EPITHELIUM; FEMALE; FOXM1 GENE; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC HETEROGENEITY; HISTOLOGY; HUMAN; HUMAN TISSUE; MICRODISSECTION; NORMAL HUMAN; PRIORITY JOURNAL; RNA SEQUENCE; TRIPLE NEGATIVE BREAST CANCER;

CASE-CONTROL STUDIES; CLUSTER ANALYSIS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; MAMMARY GLANDS, HUMAN; MICRODISSECTION; MUTATION; SEQUENCE ANALYSIS, RNA; TRANSCRIPTION, GENETIC; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84892799530     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2780-y     Document Type: Article

References (50)

1. Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA (2008) Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 14(24):8010-8018. doi: 10.1158/1078-0432.CCR- 08-1208
2. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1):4429-4434. doi: 10.1158/1078-0432.CCR-06-3045
3. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21):2492-2502. doi: 10.1001/jama.295.21.2492
4. Stark A, Kleer CG, Martin I, Awuah B, Nsiah-Asare A, Takyi V, Braman M, Quayson SE, Zarbo R, Wicha M, Newman L (2010) African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study. Cancer 116(21):4926-4932. doi: 10.1002/cncr.25276
5. Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O, Malaka D, Malami S, Odetunde A, Adeoye AO, Iyare F, Falusi A, Perou CM, Olopade OI (2009) Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol 27(27):4515-4521. doi: 10.1200/JCO.2008.19.6873
6. Ambaye AB, MacLennan SE, Goodwin AJ, Suppan T, Naud S, Weaver DL (2009) Carcinoma and atypical hyperplasia in reduction mammaplasty: increased sampling leads to increased detection. A prospective study. Plast Reconstr Surg 124(5):1386-1392. doi: 10.1097/PRS.0b013e3181b988da
7. Ishag MT, Bashinsky DY, Beliaeva IV, Niemann TH, Marsh WL Jr (2003) Pathologic findings in reduction mammaplasty specimens. Am J Clin Pathol 120(3):377-380. doi: 10.1309/4KD6-52HN-739X-TLM3
8. Ramakrishnan R, Bhandare D, Fine N, Khan SA, Lal A, Nayar R (2005) Pathologic findings in contralateral reduction mammaplasty specimens in patients with breast cancer. Breast J 11(5):372-373. doi: 10.1111/j.1075-122X.2005. 00059.x
9. Degnim AC, Visscher DW, Hoskin TL, Frost MH, Vierkant RA, Vachon CM, Shane Pankratz V, Radisky DC, Hartmann LC (2012) Histologic findings in normal breast tissues: comparison to reduction mammaplasty and benign breast disease tissues. Breast Cancer Res Treat 133(1):169-177. doi: 10.1007/s10549-011-1746-1
10. Tripathi A, King C, de la Morenas A, Perry VK, Burke B, Antoine GA, Hirsch EF, Kavanah M, Mendez J, Stone M, Gerry NP, Lenburg ME, Rosenberg CL (2008) Gene expression abnormalities in histologically normal breast epithelium of breast cancer patients. Int J Cancer 122(7):1557-1566. doi: 10.1002/ijc.23267
11. Graham K, Ge X, de Las Morenas A, Tripathi A, Rosenberg CL (2011) Gene expression profiles of estrogen receptor-positive and estrogen receptor-negative breast cancers are detectable in histologically normal breast epithelium. Clin Cancer Res 17(2):236-246. doi: 10.1158/1078-0432.CCR-10-1369
12. Yan PS, Venkataramu C, Ibrahim A, Liu JC, Shen RZ, Diaz NM, Centeno B, Weber F, Leu YW, Shapiro CL, Eng C, Yeatman TJ, Huang TH (2006) Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res 12(22):6626-6636. doi: 10.1158/1078-0432.CCR-06-0467
13. Deng G, Lu Y, Zlotnikov G, Thor AD, Smith HS (1996) Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science 274(5295):2057-2059
14. Lakhani SR, Chaggar R, Davies S, Jones C, Collins N, Odel C, Stratton MR, O'Hare MJ (1999) Genetic alterations in 'normal' luminal and myoepithelial cells of the breast. J Pathol 189(4):496-503. doi: 10.1002/(SICI)1096- 9896(199912)189:4<496:AID-PATH485>3.0.CO;2-D
15. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121(7):2750-2767. doi: 10.1172/JCI45014
16. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, Bashashati A, Prentice LM, Khattra J, Burleigh A, Yap D, Bernard V, McPherson A, Shumansky K, Crisan A, Giuliany R, Heravi-Moussavi A, Rosner J, Lai D, Birol I, Varhol R, Tam A, Dhalla N, Zeng T, Ma K, Chan SK, Griffith M, Moradian A, Cheng SW, Morin GB, Watson P, Gelmon K, Chia S, Chin SF, Curtis C, Rueda OM, Pharoah PD, Damaraju S, Mackey J, Hoon K, Harkins T, Tadigotla V, Sigaroudinia M, Gascard P, Tlsty T, Costello JF, Meyer IM, Eaves CJ, Wasserman WW, Jones S, Huntsman D, Hirst M, Caldas C, Marra MA, Aparicio S (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486(7403):395-399. doi: 10.1038/nature10933
17. Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61-70. doi: 10.1038/nature11412
18. Herschkowitz JI, He X, Fan C, Perou CM (2008) The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res 10(5):R75. doi: 10.1186/bcr2142
19. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, Langerod A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Borresen-Dale AL, Brenton JD, Tavare S, Caldas C, Aparicio S (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486(7403):346-352. doi: 10.1038/nature10983
20. Dawson SJ, Rueda OM, Aparicio S, Caldas C (2013) A new genome-driven integrated classification of breast cancer and its implications. EMBO J 32(5):617-628. doi: 10.1038/emboj.2013.19
21. Sakarya O, Breu H, Radovich M, Chen Y, Wang YN, Barbacioru C, Utiramerur S, Whitley PP, Brockman JP, Vatta P, Zhang Z, Popescu L, Muller MW, Kudlingar V, Garg N, Li CY, Kong BS, Bodeau JP, Nutter RC, Gu J, Bramlett KS, Ichikawa JK, Hyland FC, Siddiqui AS (2012) RNA-Seq mapping and detection of gene fusions with a suffix array algorithm. PLoS Comput Biol 8(4):e1002464. doi: 10.1371/journal.pcbi.1002464
22. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938-1948. doi: 10.1056/NEJMra1001389
23. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10(16):5367-5374. doi: 10.1158/1078-0432.CCR-04-0220
24. Baselga J, Gomez P, Greil R, Braga S, Climent MA, Wardley AM, Kaufman B, Stemmer SM, Pego A, Chan A, Goeminne JC, Graas MP, Kennedy MJ, Ciruelos Gil EM, Schneeweiss A, Zubel A, Groos J, Melezinkova H, Awada A (2013) Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol. doi: 10.1200/JCO.2012.46.2408
25. Baselga J, Albanell J, Ruiz A, Lluch A, Gascon P, Guillem V, Gonzalez S, Sauleda S, Marimon I, Tabernero JM, Koehler MT, Rojo F (2005) Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 23(23):5323-5333. doi: 10.1200/JCO.2005.08.326
26. Modi S, Seidman AD, Dickler M, Moasser M, D'Andrea G, Moynahan ME, Menell J, Panageas KS, Tan LK, Norton L, Hudis CA (2005) A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat 90(2):157-163. doi: 10.1007/s10549-004-3974-0
27. Finn RS, Bengala C, Ibrahim N, Roche H, Sparano J, Strauss LC, Fairchild J, Sy O, Goldstein LJ (2011) Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res 17(21):6905-6913. doi: 10.1158/1078-0432.CCR-11-0288
28. Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP (2012) TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 30(21):2615-2623. doi: 10.1200/JCO.2010.34.5579
29. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jane-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P Jr, de Silva M, Jagtap K, Jones MD, Wang L, Hatton C, Palescandolo E, Gupta S, Mahan S, Sougnez C, Onofrio RC, Liefeld T, MacConaill L, Winckler W, Reich M, Li N, Mesirov JP, Gabriel SB, Getz G, Ardlie K, Chan V, Myer VE, Weber BL, Porter J, Warmuth M, Finan P, Harris JL, Meyerson M, Golub TR, Morrissey MP, Sellers WR, Schlegel R, Garraway LA (2012) The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483(7391):603-607. doi: 10.1038/nature11003
30. Broad Institute TCGA Genome Data Analysis Center (2013) Breast invasive carcinoma (primary solid tumor cohort) - 21 April 2013: mutation analysis (MutSig v2.0). Broad Institute of MIT and Harvard. doi: 10.7908/C1JS9NC5
31. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2(5):401-404. doi: 10.1158/2159-8290.CD-12-0095
32. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6(269):pl1. doi: 10.1126/scisignal.2004088
33. Haibe-Kains B, Schroeder M, Bontempi G, Sotiriou C, Quackenbush J (2012) genefu: relevant functions for gene expression analysis, especially in breast cancer. R package version 191. http://compbio.dfci.harvard.edu
34. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8):1160-1167. doi: 10.1200/JCO.2008.18.1370
35. Heaphy CM, Griffith JK, Bisoffi M (2009) Mammary field cancerization: molecular evidence and clinical importance. Breast Cancer Res Treat 118(2):229-239. doi: 10.1007/s10549-009-0504-0
36. Trujillo KA, Heaphy CM, Mai M, Vargas KM, Jones AC, Vo P, Butler KS, Joste NE, Bisoffi M, Griffith JK (2011) Markers of fibrosis and epithelial to mesenchymal transition demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. Int J Cancer 129(6):1310-1321. doi: 10.1002/ijc.25788
37. Troester MA, Lee MH, Carter M, Fan C, Cowan DW, Perez ER, Pirone JR, Perou CM, Jerry DJ, Schneider SS (2009) Activation of host wound responses in breast cancer microenvironment. Clin Cancer Res 15(22):7020-7028. doi: 10.1158/1078-0432.CCR-09-1126
38. Roman-Perez E, Casbas-Hernandez P, Pirone JR, Rein J, Carey LA, Lubet RA, Mani SA, Amos KD, Troester MA (2012) Gene expression in extratumoral microenvironment predicts clinical outcome in breast cancer patients. Breast Cancer Res 14(2):R51. doi: 10.1186/bcr3152
39. Wang J, Scholtens D, Holko M, Ivancic D, Lee O, Hu H, Chatterton RT Jr, Sullivan ME, Hansen N, Bethke K, Zalles CM, Khan SA (2013) Lipid metabolism genes in contralateral unaffected breast and estrogen receptor status of breast cancer. Cancer Prev Res (Phila) 6(4):321-330. doi: 10.1158/1940-6207.CAPR-12- 0304
40. Muenst S, Soysal SD, Gao F, Obermann EC, Oertli D, Gillanders WE (2013) The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 139(3):667-676. doi: 10.1007/s10549-013-2581-3
41. Komatsu M, Yoshimaru T, Matsuo T, Kiyotani K, Miyoshi Y, Tanahashi T, Rokutan K, Yamaguchi R, Saito A, Imoto S, Miyano S, Nakamura Y, Sasa M, Shimada M, Katagiri T (2013) Molecular features of triple negative breast cancer cells by genome-wide gene expression profiling analysis. Int J Oncol 42(2):478-506. doi: 10.3892/ijo 2012.1744
42. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869-10874. doi: 10.1073/pnas.191367098
43. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747-752. doi: 10.1038/35021093
44. O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM, Bradley C (2011) Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364(3):205-214. doi: 10.1056/NEJMoa1011418
45. O'Shaughnessy J, Schwartzberg LS, Danso MA, Rugo HS, Miller K, Yardley DA, Carlson RW, Finn RS, Charpentier E, Freese M, Gupta S, Blackwood-Chirchir A, Winer EP (2011) A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol (Meeting Abstracts) 29 (15):suppl; abstr 1007
46. Puhalla SL, Appleman LJ, Beumer JH, Tawbi H, Stoller RG, Owonikoko TK, Ramalingam SS, Belani CP, Brufsky AM, Abraham J, Shephard SP, Giranda V, Chen AP, Chu E (2012) Two phase I trials exploring different dosing schedules of carboplatin (C), paclitaxel (P), and the poly-ADP-ribose polymerase (PARP) inhibitor, veliparib (ABT-888) (V) with activity in triple negative breast cancer (TNBC). San Antonio breast cancer symposium poster discussion
47. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2):123-134. doi: 10.1056/NEJMoa0900212
48. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376(9737):235-244. doi: 10.1016/S0140-6736(10) 60892-6
49. Wierstra I, Alves J (2007) FOXM1, a typical proliferation-associated transcription factor. Biol Chem 388(12):1257-1274. doi: 10.1515/BC.2007.159
50. Raychaudhuri P, Park HJ (2011) FoxM1: a master regulator of tumor metastasis. Cancer Res 71(13):4329-4333. doi: 10.1158/0008-5472.CAN-11-0640